A booster dose of SARS-COV-2 vaccine improves suboptimal seroconversion rates in patients with inflammatory bowel disease. Results of a prospective multicenter study of GETECCU (VACOVEII study)

Update your browser to view ScienceDirect.

Request details:

Request ID: 8ceac72a1fbe679c-LAX
IP: 116.62.10.13
UTC time: 2024-10-07T03:24:24+00:00
Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4